Human carotid lesion linoleic acid hydroperoxide inhibits paraoxonase 1 (PON1) activity via reaction with PON1 free sulfhydryl cysteine 284

Free Radical Biology and Medicine

Volumn 50, Issue 1, 2011, Pages 148-156

  Tavori, Hagai ^a,b,c   Aviram, Michael ^c   Khatib, Soliman ^a,b   Musa, Ramadan ^a,b   Mannheim, Dalit ^d   Karmeli, Ron ^d   Vaya, Jacob ^a,b  

^a MIGAL GALILEE TECHNOLOGY CENTER   (Israel)

^b TEL HAI COLLEGE   (Israel)

^c RAMBAM MEDICAL CENTER   (Israel)

^d CARMEL MEDICAL CENTER   (Israel)

Author keywords

Atherosclerosis; Carotid lesion; Free radicals; Free thiols; Linoleic acid hydroperoxide; Oxidative stress; Paraoxonase 1

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; CYSTEINE; ENZYME INHIBITOR; LINOLEIC ACID HYDROPEROXIDE; LIPID; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTERY LESION; ARTICLE; CAROTID ARTERY; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME MECHANISM; HUMAN; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ARYLDIALKYLPHOSPHATASE; CAROTID ARTERY INJURIES; CATALYTIC DOMAIN; CHO CELLS; CRICETINAE; CRICETULUS; CYSTEINE; ENZYME INHIBITORS; HUMANS; LINOLEIC ACIDS; LIPID PEROXIDES; LIPOPROTEINS, HDL; MUTANT PROTEINS; SULFHYDRYL COMPOUNDS; SULFHYDRYL REAGENTS; TISSUE EXTRACTS;

EID: 78650687313     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2010.10.708     Document Type: Article

References (45)

1. Badimon J.J., Fuster V., Chesebro J.H., and Badimon L. Coronary atherosclerosis: a multifactorial disease Circulation 87 1993 II3 II16
2. J.L. Witztum, and D. Steinberg Role of oxidized low density lipoprotein in atherogenesis J. Clin. Invest. 88 1991 1785 1792
3. J. Vaya, M. Aviram, S. Mahmood, T. Hayek, E. Grenadir, A. Hoffman, and S. Milo Selective distribution of oxysterols in atherosclerotic lesions and human plasma lipoproteins Free Radic. Res. 34 2001 485 497
4. K.L. Carpenter, S.E. Taylor, C. van der Veen, B.K. Williamson, J.A. Ballantine, and M.J. Mitchinson Lipids and oxidised lipids in human atherosclerotic lesions at different stages of development Biochim. Biophys. Acta 1256 1995 141 150
5. Marsillach, J.; Mackness, B.; Mackness, M.; Riu, F.; Beltran, R.; Joven, J.; Camp, J. Immunohistochemical analysis of paraoxonase-1, 2 and 3 in human atheroma plaques. 3rd International Conference on Paraoxoanses. UCLA, Los Angeles, California, USA. 7-10 Sep 2008.
6. B. Mackness, R. Hunt, P.N. Durrington, and M.I. Mackness Increased immunolocalization of paraoxonase, clusterin, and apolipoprotein A-I in the human artery wall with the progression of atherosclerosis Arterioscler. Thromb. Vasc. Biol. 17 1997 1233 1238
7. H. Tavori, M. Aviram, S. Khatib, R. Musa, S. Nitecki, A. Hoffman, and J. Vaya Human carotid atherosclerotic plaque increases oxidative state of macrophages and low-density lipoproteins, whereas paraoxonase 1 (PON1) decreases such atherogenic effects Free Radic. Biol. Med. 46 2009 607 615
8. M. Rosenblat, J. Vaya, D. Shih, and M. Aviram Paraoxonase 1 (PON1) enhances HDL-mediated macrophage cholesterol efflux via the ABCA1 transporter in association with increased HDL binding to the cells: a possible role for lysophosphatidylcholine Atherosclerosis 179 2005 69 77
9. B. Mackness, R. Quarck, W. Verreth, M. Mackness, and P. Holvoet Human paraoxonase-1 overexpression inhibits atherosclerosis in a mouse model of metabolic syndrome Arterioscler. Thromb. Vasc. Biol. 26 2006 1545 1550
10. D.M. Shih, C. Welch, and A.J. Lusis New insights into atherosclerosis from studies with mouse models Mol. Med. Today 1 1995 364 372
11. M.I. Mackness, B. Mackness, P.N. Durrington, P.W. Connelly, and R.A. Hegele Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins Curr. Opin. Lipidol. 7 1996 69 76
12. G.P. Jarvik, L.S. Rozek, V.H. Brophy, T.S. Hatsukami, R.J. Richter, G.D. Schellenberg, and C.E. Furlong Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1(192) or PON1(55) genotype Arterioscler. Thromb. Vasc. Biol. 20 2000 2441 2447
13. N. Martinelli, D. Girelli, O. Olivieri, P. Guarini, A. Bassi, E. Trabetti, S. Friso, F. Pizzolo, C. Bozzini, I. Tenuti, L. Annarumma, R. Schiavon, P. Franco Pignatti, and R. Corrocher Novel serum paraoxonase activity assays are associated with coronary artery disease Clin. Chem. Lab. Med. 47 2009 432 440
14. L. Gallicchio, K. Boyd, G. Matanoski, X.G. Tao, L. Chen, T.K. Lam, M. Shiels, E. Hammond, K.A. Robinson, L.E. Caulfield, J.G. Herman, E. Guallar, and A.J. Alberg Carotenoids and the risk of developing lung cancer: a systematic review Am. J. Clin. Nutr. 88 2008 372 383
15. L. Jaouad, C. de Guise, H. Berrougui, M. Cloutier, M. Isabelle, T. Fulop, H. Payette, and A. Khalil Age-related decrease in high-density lipoproteins antioxidant activity is due to an alteration in the PON1's free sulfhydryl groups Atherosclerosis 185 2006 191 200
16. M. Aviram, M. Rosenblat, S. Billecke, J. Erogul, R. Sorenson, C.L. Bisgaier, R.S. Newton, and B. La Du Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants Free Radic. Biol. Med. 26 1999 892 904
17. O. Rozenberg, and M. Aviram S-Glutathionylation regulates HDL-associated paraoxonase 1 (PON1) activity Biochem. Biophys. Res. Commun. 351 2006 492 498
18. N. Franco-Pons, J. Marsillach, J. Joven, J. Camps, and D. Closa Serum paraoxonase undergoes inhibition and proteolysis during experimental acute pancreatitis J. Gastrointest. Surg. 12 2008 891 899
19. K.R. Feingold, R.A. Memon, A.H. Moser, and C. Grunfeld Paraoxonase activity in the serum and hepatic mRNA levels decrease during the acute phase response Atherosclerosis 139 1998 307 315
20. S.D. Nguyen, and D.E. Sok Preferential inhibition of paraoxonase activity of human paraoxonase 1 by negatively charged lipids J. Lipid Res. 45 2004 2211 2220
21. L.G. Costa, A. Vitalone, T.B. Cole, and C.E. Furlong Modulation of paraoxonase (PON1) activity Biochem. Pharmacol. 69 2005 541 550
22. S.D. Nguyen, N.D. Hung, P. Cheon-Ho, K.M. Ree, and S. Dai-Eun Oxidative inactivation of lactonase activity of purified human paraoxonase 1 (PON1) Biochim. Biophys. Acta 1790 2009 155 160
23. M. Efrat, M. Rosenblat, S. Mahmood, J. Vaya, and M. Aviram Di-oleoyl phosphatidylcholine (PC-18:1) stimulates paraoxonase 1 (PON1) enzymatic and biological activities: in vitro and in vivo studies Atherosclerosis 202 2009 461 469
24. M. Aviram, E. Hardak, J. Vaya, S. Mahmood, S. Milo, A. Hoffman, S. Billicke, D. Draganov, and M. Rosenblat Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities Circulation 101 2000 2510 2517
25. M. Harel, A. Aharoni, L. Gaidukov, B. Brumshtein, O. Khersonsky, R. Meged, H. Dvir, R.B. Ravelli, A. McCarthy, L. Toker, I. Silman, J.L. Sussman, and D.S. Tawfik Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes Nat. Struct. Mol. Biol. 11 2004 412 419
26. L. Gaidukov, and D.S. Tawfik High affinity, stability, and lactonase activity of serum paraoxonase PON1 anchored on HDL with ApoA-I Biochemistry 44 2005 11843 11854
27. O. Khersonsky, and D.S. Tawfik Chromogenic and fluorogenic assays for the lactonase activity of serum paraoxonases Chembiochem 7 2006 49 53 (Pubitemid 43076285)
28. K.N. Gan, A. Smolen, H.W. Eckerson, and B.N. La Du Purification of human serum paraoxonase/arylesterase: evidence for one esterase catalyzing both activities Drug Metab. Dispos. 19 1991 100 106
29. M. Aviram Plasma lipoprotein separation by discontinuous density gradient ultracentrifugation in hyperlipoproteinemic patients Biochem. Med. 30 1983 111 118
30. O.H. Lowry, N.J. Rosebrough, A.L. Farr, and R.J. Randall Protein measurement with the Folin phenol reagent J. Biol. Chem. 193 1951 265 275
31. E. Hasnis, A.Z. Reznick, S. Pollack, Y. Klein, and R.M. Nagler Synergistic effect of cigarette smoke and saliva on lymphocytes-the mediatory role of volatile aldehydes and redox active iron and the possible implications for oral cancer Int. J. Biochem. Cell Biol. 36 2004 826 839
32. El-Saadani M., Esterbauer H., M. el-Sayed, Goher M., Nassar A.Y., and Jurgens G. A spectrophotometric assay for lipid peroxides in serum lipoproteins using a commercially available reagent J. Lipid Res. 30 1989 627 630
33. H.W. Gardner, and M.J. Grove Method to produce 9(S)-hydroperoxides of linoleic and linolenic acids by maize lipoxygenase Lipids 36 2001 529 533
34. M. Gargouri, P. Drouet, and M.D. Legoy Hydroperoxide-lyase activity in mint leaves: volatile C6-aldehyde production from hydroperoxy-fatty acids J. Biotechnol. 111 2004 59 65
35. H. Tavori, S. Khatib, M. Aviram, and J. Vaya Characterization of the PON1 active site using modeling simulation, in relation to PON1 lactonase activity Bioorg. Med. Chem. 16 2008 7504 7509
36. N. Stadler, N. Stanley, S. Heeneman, V. Vacata, M.J. Daemen, P.G. Bannon, J. Waltenberger, and M.J. Davies Accumulation of zinc in human atherosclerotic lesions correlates with calcium levels but does not protect against protein oxidation Arterioscler. Thromb. Vasc. Biol. 28 2008 1024 1030
37. D.I. Draganov, J.F. Teiber, A. Speelman, Y. Osawa, R. Sunahara, and B.N. La Du Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities J. Lipid Res. 46 2005 1239 1247
38. J.F. Teiber, D.I. Draganov, and B.N. La Du Lactonase and lactonizing activities of human serum paraoxonase (PON1) and rabbit serum PON3 Biochem. Pharmacol. 66 2003 887 896
39. M. Rosenblat, L. Gaidukov, O. Khersonsky, J. Vaya, R. Oren, D.S. Tawfik, and M. Aviram The catalytic histidine dyad of high density lipoprotein- associated serum paraoxonase-1 (PON1) is essential for PON1-mediated inhibition of low density lipoprotein oxidation and stimulation of macrophage cholesterol efflux J. Biol. Chem. 281 2006 7657 7665
40. E. Nishio, and Y. Watanabe Cigarette smoke extract inhibits plasma paraoxonase activity by modification of the enzyme's free thiols Biochem. Biophys. Res. Commun. 236 1997 289 293
41. M.A. Oliveira, B.G. Guimaraes, J.R. Cussiol, F.J. Medrano, F.C. Gozzo, and L.E. Netto Structural insights into enzyme-substrate interaction and characterization of enzymatic intermediates of organic hydroperoxide resistance protein from Xylella fastidiosa J. Mol. Biol. 359 2006 433 445
42. S. Carballal, R. Radi, M.C. Kirk, S. Barnes, B.A. Freeman, and B. Alvarez Sulfenic acid formation in human serum albumin by hydrogen peroxide and peroxynitrite Biochemistry 42 2003 9906 9914
43. L. Turell, H. Botti, S. Carballal, R. Radi, and B. Alvarez Sulfenic acid-a key intermediate in albumin thiol oxidation J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 877 2009 3384 3392
44. M. Aviram HDL-associated paraoxonase 1 (PON1) and dietary antioxidants attenuate lipoprotein oxidation, macrophage foam cells formation and atherosclerosis development Pathophysiol. Haemost. Thromb. 35 2006 146 151
45. O. Rozenberg, D.M. Shih, and M. Aviram Paraoxonase 1 (PON1) attenuates macrophage oxidative status: studies in PON1 transfected cells and in PON1 transgenic mice Atherosclerosis 181 2005 9 18